IP Library Granted Patent US 11,806,328
Granted Patent B2
US 11,806,328 · App. 17/122,479 · Granted Nov 7, 2023

Metabolic therapy for wound healing

Inventors: Dominic Paul D'Agostino (Tampa, FL); Shannon Kesl (Tampa, FL)
Assignee: UNIVERSITY OF SOUTH FLORIDA
A61K31/231A61K31/047A61K31/19A61K31/198A61K31/22A61K36/889A61P17/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,806,328
App. No.
17/122,479
Granted
Nov 7, 2023
Kind
B2
Abstract

Ketone supplementation, such as through use of precursors of beta-hydroxybutyrate (BHB) and acetoacetate (AcAc), increased blood levels of ketone bodies, increases blood flow and wound closure in ischemic young and aged fisher rats significantly earlier compared to standard diet in aged rats. In vitro experiments with ketone bodies demonstrate decreased mitochondrial and cytosolic ROS in young and aged primary human dermal fibroblasts (PHDF). Ketone bodies increased migration in young and aged PHDFs.

Claims (24)

1. A method of improving wound healing, comprising:

orally, intragastrically, intraarterially, or intravenously administering at least one ketone source to a patient in need thereof, wherein the at least one ketone source is administered to obtain ketosis in the patient, wherein the patient has an ischemic wound, and

wherein the patient is fed ad libitum and is not on a ketogenic diet.

2. The method of claim 1 , wherein the ketone source is R,S-1,3-butanediol, beta-hydroxybutyrate precursor, acetoacetate, acetoacetate precursor, or at least one medium chain triglycerides and beta-hydroxybutyrate mineral salt.

3. The method of claim 2 , wherein the beta-hydroxybutyrate precursor is a beta-hydroxybutyrate salt.

4. The method of claim 3 , wherein the beta-hydroxybutyrate salt is sodium beta-hydroxybutyrate, arginine beta-hydroxybutyrate, potassium beta-hydroxybutyrate, calcium beta-hydroxybutyrate, magnesium beta-hydroxybutyrate, lithium beta-hydroxybutyrate, lysine beta-hydroxybutyrate, histidine beta-hydroxybutyrate, ornithine beta-hydroxybutyrate, creatine beta-hydroxybutyrate, agmatine beta-hydroxybutyrate, citrulline beta-hydroxybutyrate, beta-hydroxy butyrate sodium salt, beta-hydroxy butyrate potassium salt, beta-hydroxy butyrate calcium salt, beta-hydroxy butyrate magnesium salt, or a combination thereof.

5. The method of claim 4 , wherein the ketone source is a racemic DL-beta hydroxybutyrate precursor or a single isomer R-beta hydroxybutyrate precursor.

6. The method of claim 2 , wherein the β-hydroxybutyrate ketone precursor is 1,3-butanediol, ethyl acetoacetate, and ethyl beta-hydroxybutyrate.

7. The method of claim 2 , wherein the β-hydroxybutyrate ketone precursor is administered at between 2 grams and 50 grams.

8. The method of claim 1 , wherein the ketone is administered at about 1 g/kg/day to about 10 g/kg/day.

9. The method of claim 2 , wherein the at least one medium chain triglyceride is coconut oil, coconut milk powder, fractionated coconut oil, palm oil, palm kernel oil, caprylic acid, isolated hexanoic acid, isolated octanoic acid, isolated decanoic acid, esterified ester derivatives thereof, ethoxylated derivatives thereof, enone-ylated derivatives thereof, aldehyde derivatives thereof, monoglyceride derivatives thereof, diglyceride derivatives thereof, and triglyceride derivatives thereof, salt derivatives thereof, or a combination thereof.

10. The method of claim 1 , wherein the at least one medium chain triglyceride is optionally administered at between 5 grams and 50 grams.

11. A method of reducing or treating redox stress in wound repair, comprising:

orally, intragastrically, intraarterially, or intravenously administering at least one ketone source to a patient in need thereof, wherein the at least one ketone source is administered to obtain ketosis in the patient, wherein the patient has an ischemic wound, and

wherein the patient is fed ad libitum and is not on a ketogenic diet.

12. The method of claim 11 , wherein the ketone source is R,S-1,3-butanediol, beta-hydroxybutyrate precursor, acetoacetate, acetoacetate precursor, or at least one medium chain triglycerides and beta-hydroxybutyrate mineral salt.

13. The method of claim 12 , wherein the beta-hydroxybutyrate precursor is a beta-hydroxybutyrate salt.

14. The method of claim 13 , wherein the beta-hydroxybutyrate salt is sodium beta-hydroxybutyrate, arginine beta-hydroxybutyrate, potassium beta-hydroxybutyrate, calcium beta-hydroxybutyrate, magnesium beta-hydroxybutyrate, lithium beta-hydroxybutyrate, lysine beta-hydroxybutyrate, histidine beta-hydroxybutyrate, ornithine beta-hydroxybutyrate, creatine beta-hydroxybutyrate, agmatine beta-hydroxybutyrate, citrulline beta-hydroxybutyrate, beta-hydroxy butyrate sodium salt, beta-hydroxy butyrate potassium salt, beta-hydroxy butyrate calcium salt, beta-hydroxy butyrate magnesium salt, or a combination thereof.

15. The method of claim 14 , wherein the ketone source is a racemic DL-beta hydroxybutyrate precursor or a single isomer R-beta hydroxybutyrate precursor.

16. The method of claim 12 , wherein the β-hydroxybutyrate ketone precursor is 1,3-butanediol, ethyl acetoacetate, and ethyl beta-hydroxybutyrate.

17. The method of claim 12 , wherein the β-hydroxybutyrate ketone precursor is administered at between 2 grams and 50 grams.

18. The method of claim 11 , wherein the ketone is administered at about 1 g/kg/day to about 10 g/kg/day.

19. The method of claim 12 , wherein the at least one medium chain triglyceride is coconut oil, coconut milk powder, fractionated coconut oil, palm oil, palm kernel oil, caprilic acid, isolated hexanoic acid, isolated octanoic acid, isolated decanoic acid, esterified ester derivatives thereof, ethoxylated derivatives thereof, enone-ylated derivatives thereof, aldehyde derivatives thereof, monoglyceride derivatives thereof, diglyceride derivatives thereof, and triglyceride derivatives thereof, salt derivatives thereof, or a combination thereof.

20. The method of claim 11 , wherein the at least one medium chain triglyceride is optionally administered at between 5 grams and 50 grams.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2020
From: D'AGOSTINO, DOMINIC PAUL; KESL, SHANNON
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 054662/0651 →
Continuity (3)
Continuation 14554172 · Nov 26, 2014
Provisional Application 61909811 · Nov 27, 2013
Related Publication 20210093602A1 · Apr 1, 2021